If you have been reading about aliquoting and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Handling begins before a peptide arrives at the bench. Containers should be inspected for cracks, loose caps, or visible moisture, and labels should record identity, lot, and receipt date. Lyophilized material is often allowed to equilibrate to room temperature before opening to prevent condensation on the powder. Gloves and a clean workspace reduce contamination and static-related loss. Once opened, the vial may be purged with inert gas and resealed if the peptide is sensitive to oxygen or humidity. These steps are procedural safeguards rather than guarantees of stability.
Reconstitution introduces new risks because the peptide contacts solvent, air, and container surfaces. The chosen solvent should match the peptide's solubility profile, and buffer salts, pH, and ionic strength can affect dissolution and subsequent stability. Gentle mixing is preferred over vigorous vortexing, which can create interfaces and shear. If the solution is not clear, the cause may be incomplete dissolution, aggregation, or insoluble counter-ions rather than a simple concentration problem. Filtration is sometimes used, but filters can adsorb peptides and alter measured concentration.
Cold-chain practice relies on documented temperature ranges, calibrated monitoring, and minimized excursions. Shipments may use insulated boxes, phase-change materials, or dry ice, with data loggers to record conditions. Upon receipt, the recipient should verify the logger trace and place items into long-term storage promptly. Repeated warming and cooling during transfers can be more harmful than a single controlled excursion. For solutions, dividing material into single-use aliquots reduces the number of thawing and refreezing events and limits repeated opening of the same container.
Aliquoting reduces repeated temperature cycling for solutions and reconstituted samples. If a peptide is supplied as a powder, reconstitution usually involves adding a suitable solvent gently along the vial wall. Mixing by inversion or slow swirling is preferred over vortexing, which can create air-liquid interfaces that promote aggregation or foaming. The resulting solution should be inspected for clarity, particles, and color before storage. Labels on aliquots typically include concentration, solvent, date, and lot number, and open questions remain about the best solvent for every sequence.
Quality control relies on analytical methods that detect changes in purity, identity, and concentration. Reverse-phase high-performance liquid chromatography separates the parent peptide from degradation products, while mass spectrometry confirms molecular mass. Water content can be measured by Karl Fischer titration, and amino acid analysis or peptide mapping may reveal sequence-level modifications. Stability studies compare stored samples against baseline material at defined intervals. Documentation should link each result to a lot number, storage condition, and test date so that trends can be reviewed.
Receipt and inventory practices begin with inspection of packaging, temperature indicators, and lot-specific documentation. A certificate of analysis typically reports purity, identity, and sometimes residual water or counterion content. Containers should be labeled with the peptide name, lot number, date received, and storage location. Before a sealed vial is opened, it is often equilibrated to room temperature to reduce condensation on the contents. Clean tools, gloves, and a designated workspace limit contamination and accidental adsorption losses.
| Property | Value | Notes |
|---|---|---|
| Container material | Glass or polypropylene | Low-binding options reduce peptide adsorption |
| Typical shipping condition | Dry ice or gel packs | Choice depends on required temperature range |
| Light protection | Amber vial or foil wrap | Reduces photodegradation of sensitive residues |
| Reconstitution solvent | Water, buffer, or organic co-solvent | Depends on peptide solubility and assay requirements |
| Temperature monitoring | Data logger or indicator | Documents excursions during transport and storage |
Handling begins when a peptide container is opened. Hygroscopic solids can absorb atmospheric water rapidly, so bench work should be brief and containers resealed with fresh desiccant. Weighing or transferring should occur in a low-humidity environment where possible. Static electricity may cause fine powders to cling to surfaces, leading to inaccurate mass measurements. Tools such as antistatic devices or grounded workstations reduce that problem. Good laboratory practice also includes labeling date, lot, and storage condition after each opening.
Reconstitution introduces new variables. The solvent should match the peptide's solubility profile, and water or buffer quality matters because trace metals and microbes can alter results. Adding solvent gently down the vial wall minimizes foaming, which can denature some sequences. Mixing by gentle inversion or swirling is usually preferred over vigorous vortexing. If a peptide does not dissolve readily, adjusting pH or using a small amount of organic co-solvent may help, but such steps can also affect stability and should be documented.
Quality control links handling to measurable identity and purity. Reverse-phase high-performance liquid chromatography can separate peptide variants and reveal impurities. Mass spectrometry confirms molecular mass and can detect truncations or modifications. These methods are often paired with ultraviolet absorbance or amino acid analysis for concentration. Documentation of instrument settings, column type, and reference standards supports reproducibility. For research materials, acceptance criteria depend on the intended application, and no universal purity threshold applies to all peptides.
Reconstitution involves adding a solvent to dry peptide, often water or a buffered solution. The chosen liquid should match the peptide's solubility and intended assay, and it should be free of contaminants. Gentle mixing or inversion reduces foaming and shear, which can damage some peptides. If the peptide does not dissolve readily, adjusting pH or using a small amount of organic co-solvent may help. The final solution is typically clarified before use in analytical or laboratory procedures.
After reconstitution, solutions are usually divided into single-use aliquots to limit repeated handling. Each aliquot is stored at a temperature appropriate for the peptide, with -20 °C or -80 °C common for longer-term laboratory storage. Freeze-thaw cycles are minimized because they can cause aggregation, precipitation, or loss of activity. Temperature monitoring and documented storage conditions support reproducibility across experiments. When a peptide is removed from storage, it is typically allowed to equilibrate before opening to reduce condensation.
Receiving a peptide begins with recording its identity, lot number, quantity, and arrival condition. Dry material is often kept in sealed containers with desiccant and an inert headspace to limit moisture and oxygen. Containers should be compatible with the peptide and solvent; some peptides adsorb to certain plastics or glass. Labels should include date, concentration, solvent, and storage location. A centralized inventory with temperature logs helps prevent loss and mix-ups.
=== Corruption === The phosphates sector – accounting for 40% of export revenues – is managed at the office of the president, and Abdi Latif Dahir, based on the Panama Papers, stated that contracts and permits to manage the sector are sold to benefit the president.
An Ommaya reservoir is an intraventricular catheter system that can be used for the aspiration of cerebrospinal fluid or for the delivery of drugs (e.g. chemotherapy) into the cerebrospinal fluid. It consists of a catheter in one lateral ventricle attached to a reservoir implanted under the scalp. It is used to treat brain tumors, leukemia/lymphoma or leptomeningeal disease by intrathecal drug administration. In the palliative care of terminal cancer, an Ommaya reservoir can be inserted for intracerebroventricular injection (ICV) of morphine. It was originally invented in 1963 by Ayub K. Ommaya, a Pakistani-American neurosurgeon. In January 2017, researchers at University of Texas Southwestern Medical Centre used an Ommaya reservoir to measure the intracranial pressure that is regularly observed in astronauts in zero-gravity conditions.
Semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes, and an anti-obesity medication used for weight management. It can be administered by subcutaneous injection or taken orally. It is sold as a generic drug by several drug companies in the Indian and Canadian markets, and worldwide by its originator, Novo Nordisk, under the brand names Ozempic and Rybelsus for diabetes; under the brand name Wegovy for weight management; and under the brand names Wegovy and Kayshild for the treatment of metabolic-associated steatohepatitis (nonalcoholic steatohepatitis) and liver cirrhosis. Wegovy is also used to reduce the risk of heart attacks. Semaglutide is a peptide similar to the hormone glucagon-like peptide-1 (GLP-1), modified with a side chain, and acts as a GLP-1 receptor agonist. The most common side effects include nausea, vomiting, diarrhea, abdominal pain, and constipation. Semaglutide was approved for medical use in the United States in 2017, in Canada, the European Union and Japan in 2018, and in Australia in 2019. In 2023, it was the nineteenth most commonly prescribed medication in the United States, with more than 25 million prescriptions. It is on the World Health Organization's List of Essential Medicines.
=== Cytotoxic T-cell responses === One of the advantages of DNA vaccines is that they are able to induce cytotoxic T lymphocytes (CTL) without the inherent risk associated with live vaccines. CTL responses can be raised against immunodominant and immunorecessive CTL epitopes, as well as subdominant CTL epitopes, in a manner that appears to mimic natural infection. This may prove to be a useful tool in assessing CTL epitopes and their role in providing immunity. Cytotoxic T-cells recognise small peptides (8-10 amino acids) complexed to MHC class I molecules. These peptides are derived from cytosolic proteins that are degraded and delivered to the nascent MHC class I molecule within the endoplasmic reticulum (ER). Targeting gene products directly to the ER (by the addition of an ER insertion signal sequence at the N-terminus) should thus enhance CTL responses. This was successfully demonstrated using recombinant vaccinia viruses expressing influenza proteins, but the principle should also be applicable to DNA vaccines. Targeting antigens for intracellular degradation (and thus entry into the MHC class I pathway) by the addition of ubiquitin signal sequences, or mutation of other signal sequences, was shown to be effective at increasing CTL responses. CTL responses can be enhanced by co-inoculation with co-stimulatory molecules such as B7-1 or B7-2 for DNA vaccines against influenza nucleoprotein, or GM-CSF for DNA vaccines against the murine malaria model P. yoelii.
Sources: en.wikipedia.org
=== Uracil substitution for thymine === Whereas DNA contains thymine (T), RNA contains uracil (U). During the process of transcription, the enzyme RNA polymerase incorporates uracil opposite adenine bases located on the DNA template strand. Therefore, the resulting RNA transcript contains uracil in the positions where the coding DNA strand contains thymine. Structurally, uracil–adenine (U–A) base pairs closely resemble thymine–adenine (T–A) base pairs, which ensures that the genetic information carried by the sequence is faithfully preserved. A frequently cited explanation for the presence of thymine in DNA involves the necessity of genome maintenance. Because cytosine can spontaneously deaminate to form uracil, DNA repair systems recognize uracil as a form of damage. The utilization of thymine as a standard base allows the cell to distinguish legitimate bases from errors, thereby maintaining uracil as a specific signal for repair.
The Weekly with Charlie Pickering is an Australian news satire series on the ABC. The series premiered on 22 April 2015, and Charlie Pickering as host with Tom Gleeson, Adam Briggs, Kitty Flanagan (2015–2018) in the cast, and Judith Lucy joined the series in 2019. The first season consisted of 20 episodes and concluded on 22 September 2015. The series was renewed for a second season on 18 September 2015, which premiered on 3 February 2016. The series was renewed for a third season with Adam Briggs joining the team and began airing from 1 February 2017. The fourth season premiered on 2 May 2018 at the later timeslot of 9:05pm to make room for the season return of Gruen at 8:30pm, and was signed on for 20 episodes. Flanagan announced her departure from The Weekly With Charlie Pickering during the final episode of season four, but returned for The Yearly with Charlie Pickering special in December 2018. In 2019, the series was renewed for a fifth season with Judith Lucy announced as a new addition to the cast as a "wellness expert". The show was pre-recorded in front of an audience in ABC's Ripponlea studio on the same day of its airing from 2015 to 2017. In 2018, the fourth season episodes were pre-recorded in front of an audience at the ABC Southbank Centre studios. In 2020, the show was filmed without a live audience due to COVID-19 pandemic restrictions and comedian Luke McGregor joined the show as a regular contributor.
=== Administration === Thiotepa is mainly administered intravenously and intravesically. The administered dose regarding different types of cancer variates between 3 mg/kg/day to 13 mg/kg/day. Thiotepa is unreliably absorbed from the gastrointestinal tract: acid instability prevents thiotepa from being administered orally. Thiotepa is also used in the treatment of bladder cancer during this treatment thiotepa is used as intravesical chemotherapy. Thiotepa is frequently administered in combination with other chemotherapeutic agents such as busulfan and carboplatin.
Sources: en.wikipedia.org
Allow the sealed vial to reach room temperature before opening to reduce condensation. Use a suitable solvent and gentle mixing rather than vigorous agitation. Follow the supplier's solubility information when available.
Aliquots limit repeated thawing and refreezing and repeated vial opening, both of which can promote degradation. They also reduce the chance of contaminating an entire batch. Single-use portions should be labeled with identity, concentration, solvent, and date.
Inspect the package for damage and confirm that temperature indicators or data loggers stayed within the specified range. Check the vial condition and labeling before placing it into storage. Record any excursion or discrepancy for the supplier or quality system.
Allow the sealed vial to equilibrate to room temperature so condensation does not form on the powder or solution. Wipe the exterior with a suitable disinfectant if the workspace requires it. Open the vial in a clean, draft-free area to reduce contamination.